ES2911038T3 - Procedimiento temprano y no invasivo para evaluar el riesgo de un sujeto de tener adenocarcinoma ductal pancreático y procedimientos de tratamiento de dicha enfermedad - Google Patents

Procedimiento temprano y no invasivo para evaluar el riesgo de un sujeto de tener adenocarcinoma ductal pancreático y procedimientos de tratamiento de dicha enfermedad Download PDF

Info

Publication number
ES2911038T3
ES2911038T3 ES17710554T ES17710554T ES2911038T3 ES 2911038 T3 ES2911038 T3 ES 2911038T3 ES 17710554 T ES17710554 T ES 17710554T ES 17710554 T ES17710554 T ES 17710554T ES 2911038 T3 ES2911038 T3 ES 2911038T3
Authority
ES
Spain
Prior art keywords
pig
antibody
level
ductal adenocarcinoma
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17710554T
Other languages
English (en)
Spanish (es)
Inventor
Kim In-San
Philippe Bertolino
Ana Hennino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kist Korea Institute Of Science And Tech
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Centre Léon Bérard
Université Claude Bernard Lyon 1
Korea Institute of Science and Technology
Original Assignee
Kist Korea Institute Of Science And Tech
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Centre Léon Bérard
Université Claude Bernard Lyon 1
Korea Institute of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kist Korea Institute Of Science And Tech, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Centre Léon Bérard, Université Claude Bernard Lyon 1, Korea Institute of Science and Technology filed Critical Kist Korea Institute Of Science And Tech
Application granted granted Critical
Publication of ES2911038T3 publication Critical patent/ES2911038T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES17710554T 2016-03-15 2017-03-15 Procedimiento temprano y no invasivo para evaluar el riesgo de un sujeto de tener adenocarcinoma ductal pancreático y procedimientos de tratamiento de dicha enfermedad Active ES2911038T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305276 2016-03-15
PCT/EP2017/056150 WO2017158043A1 (en) 2016-03-15 2017-03-15 Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatement of such disease

Publications (1)

Publication Number Publication Date
ES2911038T3 true ES2911038T3 (es) 2022-05-17

Family

ID=55588194

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17710554T Active ES2911038T3 (es) 2016-03-15 2017-03-15 Procedimiento temprano y no invasivo para evaluar el riesgo de un sujeto de tener adenocarcinoma ductal pancreático y procedimientos de tratamiento de dicha enfermedad
ES20195759T Active ES2944259T3 (es) 2016-03-15 2017-03-15 Procedimiento para activar la respuesta antitumoral de linfocitos T CD8+ de un paciente afectado con un cáncer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES20195759T Active ES2944259T3 (es) 2016-03-15 2017-03-15 Procedimiento para activar la respuesta antitumoral de linfocitos T CD8+ de un paciente afectado con un cáncer

Country Status (10)

Country Link
US (2) US11740243B2 (enExample)
EP (2) EP3430404B1 (enExample)
JP (3) JP6903680B2 (enExample)
KR (2) KR102402444B1 (enExample)
DK (2) DK3430404T3 (enExample)
ES (2) ES2911038T3 (enExample)
FI (1) FI3779447T3 (enExample)
HR (2) HRP20220335T1 (enExample)
PL (2) PL3779447T3 (enExample)
WO (1) WO2017158043A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3779447T3 (pl) * 2016-03-15 2023-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Sposób aktywowania przeciwnowotworowej odpowiedzi komórek t cd8+ u pacjenta dotknego nowotworem
CN112955462B (zh) * 2018-10-18 2024-05-07 国家医疗保健研究所 用于治疗实体瘤的βIG-H3拮抗剂和免疫检查点抑制剂的组合
KR102169346B1 (ko) * 2019-03-27 2020-10-23 덕성여자대학교 산학협력단 이종이식 동물 모델의 제조방법 및 이종이식 성공 여부 판별 방법
CN118076633A (zh) 2021-07-29 2024-05-24 法国国家健康与医学研究院 人源化抗-人βig-h3蛋白及其用途
WO2025068157A1 (en) * 2023-09-25 2025-04-03 Stromacare COMBINATION OF A βIG-H3 ANTAGONIST AND A PDFG-AA ANTAGONIST FOR THE TREATMENT OF CANCER
WO2025224297A1 (en) * 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US20050164197A1 (en) * 2002-04-19 2005-07-28 In-San Kim Method for measuring the amount of betaig-h3 protein and diagnostic kit using the same
KR20060056445A (ko) 2004-11-19 2006-05-24 주식회사 리젠 바이오텍 인간 βｉｇ－ｈ３에 대한 단클론 항체
ITVI20050059A1 (it) * 2005-03-04 2006-09-05 Consorzio Per Gli Studi Universitari In Verona Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali
EP2463657A1 (en) * 2010-12-13 2012-06-13 Université de Liège Biomarkers, uses of biomarkers and a method of identifying biomarkers
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
US9845471B2 (en) * 2013-01-15 2017-12-19 Fred Hutchinson Cancer Research Center Compositions and methods for treating pancreatic cancer
KR101515700B1 (ko) 2013-05-15 2015-04-27 경북대학교 산학협력단 Tgfbi를 이용한 패혈증 진단용 조성물 및 이를 이용한 패혈증 예방 또는 치료용 약학적 조성물과 이의 스크리닝 방법
WO2015200790A2 (en) 2014-06-26 2015-12-30 Yale University Compositions and methods to regulate renalase in the treatment of diseases and disorders
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
PL3779447T3 (pl) * 2016-03-15 2023-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Sposób aktywowania przeciwnowotworowej odpowiedzi komórek t cd8+ u pacjenta dotknego nowotworem
KR102082344B1 (ko) * 2018-06-21 2020-02-27 조성은 담도암의 진단 또는 예후 예측용 바이오마커 및 이의 용도

Also Published As

Publication number Publication date
EP3779447A1 (en) 2021-02-17
KR102408161B1 (ko) 2022-06-13
FI3779447T3 (fi) 2023-04-21
WO2017158043A1 (en) 2017-09-21
EP3430404A1 (en) 2019-01-23
HRP20220335T1 (hr) 2022-05-13
US12140594B2 (en) 2024-11-12
DK3430404T3 (da) 2022-03-21
DK3779447T3 (da) 2023-04-24
EP3430404B1 (en) 2022-01-05
JP2023052360A (ja) 2023-04-11
KR102402444B1 (ko) 2022-05-27
KR20180120716A (ko) 2018-11-06
HRP20230391T1 (hr) 2023-07-07
KR20210059020A (ko) 2021-05-24
PL3779447T3 (pl) 2023-06-26
US20240159759A1 (en) 2024-05-16
US11740243B2 (en) 2023-08-29
US20190086417A1 (en) 2019-03-21
EP3779447B1 (en) 2023-02-08
JP7569741B2 (ja) 2024-10-18
ES2944259T3 (es) 2023-06-20
JP2019512695A (ja) 2019-05-16
JP2021119146A (ja) 2021-08-12
PL3430404T3 (pl) 2022-05-02
JP6903680B2 (ja) 2021-07-14

Similar Documents

Publication Publication Date Title
ES2944259T3 (es) Procedimiento para activar la respuesta antitumoral de linfocitos T CD8+ de un paciente afectado con un cáncer
US10618954B2 (en) CKAP4-molecular-targeted antitumor agent
US10383925B2 (en) Cancer antigen EEF2
US20190271702A1 (en) Methods of treatement of cancer disease by targetting tumor associated macrophage
US20210340240A1 (en) Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
KR102944302B1 (ko) Ednra 억제제를 유효성분으로 포함하는 대장암의 예방 또는 치료용 약학적 조성물
US20200088732A1 (en) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
US20230070181A1 (en) Methods of treatment of cancer disease by targeting an epigenetic factor
US20110039789A1 (en) Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer
EP2691525A1 (en) Treatment and prognosis of solid tumour cancers
WO2026013153A1 (en) Methods of prognosis and treatment of patients suffering from myc-high tumors
JP2025077049A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング
CN121041442A (zh) 膜型glyr1分子作为胰腺癌治疗靶点的应用
CN115884983A (zh) 抗上皮细胞黏附分子抗体于癌症治疗之用途
WO2014034798A1 (ja) 癌の検出方法、診断薬および診断キット並びに癌治療用医薬組成物
US20150166667A1 (en) Methods and compositions for treating cancer